Agios Pharmaceuticals, Inc. (AGIO)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
40.55 USD
-0.68
(-1.649%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 40.55 |
Hot Take ↕ | July 11, 2026, 4:45 a.m. EDT
The immediate catalyst driving this trade is the FDA Priority Review tag for Mitapivat in sickle cell disease, which has ignited a speculative frenzy. However, the underlying business remains a classic biotech value trap: negative earnings, negative free cash flow, and a lack of commercial revenue. While the recent price action shows a massive intraday spike followed by a pullback, the technicals suggest the rally is exhausting itself. The options market confirms this tension; the heavy put volume at deep discounts acts as a circuit breaker, limiting the upside potential despite the bullish headlines. For the long term, the company lacks the cash flow to sustain operations without dilution, and the multi-year price trajectory shows a net decline, indicating the market has already priced out the worst-case scenarios. This is a high-risk, binary event-driven play, not a fundamental investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.088862 |
| AutoETS | 0.099851 |
| AutoARIMA | 0.101855 |
| AutoTheta | 0.111983 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 15.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.004 |
| Excess Kurtosis | 0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.223 |
| Revenue per Share | 1.133 |
| Market Cap | 2,411,573,760 |
| Forward P/E | -8.84 |
| Beta | 0.54 |
| Website | https://www.agios.com |
As of July 11, 2026, 4:45 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. There is heavy open interest in deep out-of-the-money puts (strikes 12.5, 25, 30) suggesting a fear of a sharp drop or a 'crash' scenario, while call activity is concentrated in the money and at-the-money strikes. The skew towards lower strikes indicates a defensive stance where traders are buying protection against downside risk, likely anticipating clinical trial results or regulatory hurdles that could cause a gap down.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.050981402 |
| Address1 | 88 Sidney Street |
| All Time High | 138.85 |
| All Time Low | 15.77 |
| Ask | 50.95 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,404,490 |
| Average Daily Volume3 Month | 1,159,621 |
| Average Volume | 1,159,621 |
| Average Volume10Days | 1,404,490 |
| Beta | 0.54 |
| Bid | 29.1 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 18.69 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.55 |
| Current Ratio | 14.187 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 41.1 |
| Day Low | 39.43 |
| Debt To Equity | 3.223 |
| Display Name | Agios Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,441,600 |
| Earnings Call Timestamp Start | 1,785,441,600 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | -470,265,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.637 |
| Enterprise To Revenue | 25.895 |
| Enterprise Value | 1,710,280,704 |
| Eps Current Year | -6.2025 |
| Eps Forward | -4.5875 |
| Eps Trailing Twelve Months | -7.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.4674 |
| Fifty Day Average Change | 9.0826 |
| Fifty Day Average Change Percent | 0.28863522 |
| Fifty Two Week Change Percent | 5.0981402 |
| Fifty Two Week High | 46.0 |
| Fifty Two Week High Change | -5.450001 |
| Fifty Two Week High Change Percent | -0.118478276 |
| Fifty Two Week Low | 22.24 |
| Fifty Two Week Low Change | 18.31 |
| Fifty Two Week Low Change Percent | 0.82329136 |
| Fifty Two Week Range | 22.24 - 46.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,374,672,600,000 |
| Float Shares | 50,061,416 |
| Forward Eps | -4.5875 |
| Forward P E | -8.839236 |
| Free Cashflow | -267,222,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 539 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -288,471,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0112 |
| Held Percent Institutions | 1.0929 |
| Implied Shares Outstanding | 59,471,609 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Agios Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,411,573,760 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_46539787 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -422,603,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,452,014,439 |
| Number Of Analyst Opinions | 8 |
| Open | 40.67 |
| Operating Cashflow | -380,408,000 |
| Operating Margins | -5.30343 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 649 8600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 40.55 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 41.23 |
| Price Eps Current Year | -6.5376863 |
| Price Hint | 2 |
| Price To Book | 2.1696093 |
| Price To Sales Trailing12 Months | 36.512444 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.799 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -0.68 |
| Regular Market Change Percent | -1.64929 |
| Regular Market Day High | 41.1 |
| Regular Market Day Low | 39.43 |
| Regular Market Day Range | 39.43 - 41.1 |
| Regular Market Open | 40.67 |
| Regular Market Previous Close | 41.23 |
| Regular Market Price | 40.55 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 713,928 |
| Return On Assets | -0.2169 |
| Return On Equity | -0.32814997 |
| Revenue Growth | 1.377 |
| Revenue Per Share | 1.133 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 59,471,609 |
| Shares Percent Shares Out | 0.11359999 |
| Shares Short | 6,756,481 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,926,807 |
| Short Name | Agios Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1148 |
| Short Ratio | 5.64 |
| Source Interval | 15 |
| State | MA |
| Symbol | AGIO |
| Target High Price | 59.0 |
| Target Low Price | 31.0 |
| Target Mean Price | 42.625 |
| Target Median Price | 43.5 |
| Total Cash | 737,038,016 |
| Total Cash Per Share | 12.393 |
| Total Debt | 35,745,000 |
| Total Revenue | 66,048,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.8431 |
| Two Hundred Day Average Change | 8.7069 |
| Two Hundred Day Average Change Percent | 0.27343127 |
| Type Disp | Equity |
| Volume | 713,928 |
| Website | https://www.agios.com |
| Zip | 2,139 |